Menu Search
Equities

China Resources Pharmaceutical Group Ltd

3320:HKG

China Resources Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.27
  • Today's Change-0.06 / -1.13%
  • Shares traded4.47m
  • 1 Year change+3.54%
  • Beta0.6609
Data delayed at least 15 minutes, as of Nov 22 2024 03:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform6
Hold1
Sell0
Strong Sell0

Share price forecast in HKD

The 10 analysts offering 12 month price targets for China Resources Pharmaceutical Group Ltd have a median target of 7.12, with a high estimate of 9.90 and a low estimate of 5.90. The median estimate represents a 33.58% increase from the last price of 5.33.
High85.7%9.90
Med33.6%7.12
Low10.7%5.90

Dividends

In 2023, China Resources Pharmaceutical Group Ltd reported a dividend of 0.15 CNY, which represents a 9.16% increase over last year. The 8 analysts covering the company expect dividends of 0.17 HKD for the upcoming fiscal year.
Div growth (TTM)9.16%
More ▼

Earnings history & estimates in HKD

China Resources Pharmaceutical Group Ltd reported annual 2023 earnings of 0.674 per share on Mar 26, 2024.
Average growth rate+6.88%
More ▼

Revenue history & estimates in HKD

China Resources Pharmaceutical Group Limited had revenues for the full year 2023 of 270.52bn. This was 6.46% above the prior year's results.
Average growth rate+7.49%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.